You are here:
Home / Archives for AMGN
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference
This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the year.
We [...]
Filed under Articles · Tagged with 2010 outlook, Akorn, AKRX, Amgen, AMGN, AnaptysBio, AstraZeneca, AZN, Bayer, BioLeap, biotechnology, BMY, Bristol-Myers Squibb Company, Cell Therapeutics, CEPH, Cephalon, Ception Therapeutics, Chiral Quest, CrystalGenomics, CTIC, CYCC, Cyclacel Pharmaceuticals, ENMD, EntreMed, FORMA Therapeutics, GDNF, glial cell line-derived neurotrophic factor, JP Morgan Healthcare Conference, KaloBios Pharmaceuticals, life sciences, MDCO, MDT, MedGenesis Therapeutix, Medicines Company, Medtronic, Novartis AG, NUVA, NuVasive, NVS, Peptimmune, Progentix Orthobiology, protein-protein interactions, Proteus Biomedical, roche, Rosetta Genomics, ROSG, Sanofi-Aventis, SNGX.OB, SNY, Soligenix, Trillium therapeutics, VentiRx Pharma, ZGEN, ZymoGenetics
On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we [...]
Filed under Articles · Tagged with Amgen, AMGN, AMLN, Amylin Pharmaceuticals, BIIB, Biogen Idec, biotechnology, BTK, CELG, Celgene, Dendreon, DNDN, ENZN, Enzon Pharmaceuticals, GENZ, Genzyme General, GILD, Gilead Sciences, GTx Inc, GTXI, HGSI, Human Genome Sciences, Impax Laboratories, IPXL, life sciences, NASDAQ Biotech Index, NBI, NPS Pharmaceuticals, NPSP, NYSE Arca Biotechnology Index, OGXI, Oncogenex Pharmaceuticals, OSIR, Osiris Therapeutics, PGNX, Progenics Pharmaceuticals, Salix Pharmaceuticals, Santarus, SLXP, SNGX, SNTS, Soligenix, Vanda Pharmaceuticals, VNDA
In January 2007, Amgen, Inc. (AMGN) obtained an option from Cytokinetics, Inc. (CYTK) to commercialize a novel small-molecule therapeutic product candidate that activates cardiac myosin with potential applications in the treatment of heart failure. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into [...]
Filed under Articles · Tagged with Aastrom Biosciences, Aldagen, Amgen, AMGN, Amorcyte, Angioblast Systems, ASTM, BHRT, Bioheart, Cardiac Repair Cells, Cardiome Pharma, cardiomyocytes, cardiovascular disease, Cardioxyl Pharmaceuticals, Celladon Corporation, CK-1827452, Cordex Pharmaceutical, CRME, CV Therapeutics, CYTK, Cytokinetics, GERN, Geron Corporation, GILD, Gilead Sciences, heart disease, heart failure, ischemic heart disease, JNJ, Johnson & Johnson, Merck, MRK, MYDICAR, MyoCell, Myogen, Natrecor, NovaCardia, omecamtiv mecarbil, Palatin Technologies, PL-3994, PTN, RegeneRx Biopharmaceuticals, Revascor, RGN, RGN-352, Scios
Parkinson’s disease [PD] is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60. Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year. PD is both a chronic and progressive disease.
While the precise cause [...]
Filed under Articles · Tagged with AAV, Addex Pharmaceuticals, adeno-associated virus, Amgen, AMGN, Amicus Therapeutics, Amsterdam Molecular Therapeutics, AVGN, Avigen, BDNF, CERE-120, Ceregene, CNS Protein Therapeutics, deep brain stimulation, DEPO, Depomed, dopamine, dopaminergic neurons, FOLD, GDNF, gene therapy, GENZ, Genzyme Corporation, glutamic acid decarboxylase, Impax Pharmaceuticals, Inc., IPX066, IPXL, L-dopa, LentiVector, levodopa, MANF, MDT, Medtronic, mesencephalic astrocyte-derived neurotrophic factor, Neurogen Corporation, Neurologix, neurotrophic factors, neurturin, NLX-P101, NRGN, NRGX, Oxford BioMedica, Parkinson's disease, PRAN, Prana Biotechnology, ProSavin, SynchoMed, Synergen, Unified Parkinson’s Disease Rating Scale
